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In plants and invertebrates, small silencing RNAs function in antiviral defense and developmental patterning
through pathways that were so far considered genetically distinct. In a recent issue of Cell, Sabin and
colleagues report the identification ofDrosophila Ars2, a protein required for both these small RNA-mediated
functions.Viruses are obligate intracellular patho-
gens of all life forms, and organisms have
evolved diverse mechanisms to combat
their aggressions. One mechanism, RNA
silencing, involves small RNAs, 19–30
nucleotides in length, that repress gene
expression by annealing to target RNA
or DNA. Silencing small RNAs include
small-interfering RNAs (siRNAs) and
microRNAs (miRNAs), which are both pro-
cessed from double-stranded (ds)RNA by
the RNaseIII Dicer. siRNAs derive from
perfectly-to-near-perfectly base-paired
dsRNAs of endogenous or exogenous
origin, including viruses. miRNAs originate
from primary miRNA transcripts (pri-
miRNA) produced from independent
transcription units found in intergenic or
intronic nuclear DNA. pri-miRNAs contain
imperfect intramolecular stem loops,
which, in animals, are first excised in the
nucleus by the Microprocessor complex,
primarily composed of the Dicer-like
enzyme Drosha and binding partner,
Pasha. Dicer then cytoplasmically con-
verts the resulting precursor miRNA
(pre-miRNA) into a single, mature miRNA
(Figure 1A). miRNAs are important cell-
fate determinants; consequently, miRNA-
deficient organisms display severe-to-
lethal developmental defects.
miRNAs and siRNAs incorporate RNA-
induced silencing complexes (RISCs),
assembled upon loading of one selected
small RNA strand into an Argonaute
(Ago) protein family member. siRNA- and
miRNA-programmed RISCs then repress
target gene expression through endonu-
cleolysis or translational repression of fully
or partially complementary mRNAs (Fig-
ures 1A and 1B). In Drosophila, miRNAs
and siRNAs are produced by two separate
Dicers, Dcr1 and Dcr2—and also distinctlyeffected by Ago1 and Ago2, respectively.
The fact that many viruses infect and are
transmitted by insects was probably an
important driving force leading to the
separation of siRNA and miRNA pathways
in arthropods (Obbard et al., 2006). Sev-
eral studies have now established that
Dcr2 generates siRNAs from viral dsRNA,
a common replication intermediate of
most viruses. siRNA-loaded Ago2 then
executes antiviral silencing by targeting
viral RNAs with sequences complemen-
tary to the siRNAs (Figure 1B). Accord-
ingly, Drosophila dcr2 and ago2 mutants
are developmentally normal, but hyper-
susceptible to viruses (reviewed in Ding
and Voinnet, 2007).
Sabin and colleagues now report the
isolation of Ars2, a novel, general antiviral
silencing factor in Drosophila. Ars2 was
isolated in a small-throughput RNAi-
based genetic screen aimed at identifying
virus-restricting host factors in cultured S2
cells (Sabin et al., 2009). The screen
employed Vesicular Stomatitis virus,
modified to contain a GFP reporter gene.
Among100 individual gene knockdowns
tested, Ars2 depletion consistently
caused a 5-fold increase in the number
of GFP-positive cells. Several additional
viruses displayed enhanced infection
rates that did not result from increased
internalization of viral antigens (measuring
viral entry into cells), but rather from
improved viral RNA replication possibly
inherent to defects in the siRNA pathway,
because the viruses tested were previ-
ously characterized as being susceptible
to RNA silencing. Ars2-depleted cells
were indeed less competent to silence
expression of sensor transgenes reporting
the activity of Dcr2-dependent siRNAs
produced from exogenous or endoge-Cell Host & Microbnous dsRNA. The effect was, however, by-
passed if siRNAs were delivered directly
into cells, suggesting that Ars2 acts up-
stream of RISC. Accordingly, Ars2 was
required for endogenous siRNA accumu-
lation and was coimmunoprecipitated
with Dcr2. Moreover, extracts of Ars2-
depleted cells produced less siRNAs
from labeled dsRNA compared to extracts
of control cells. Thus, Ars2 apparently
facilitates Dcr2 action, possibly through
direct protein-protein interactions. These
findings are relevant to authentic infec-
tions because adult flies in which Ars2
expression was conditionally suppressed
succumbed to viruses more rapidly than
control flies.
Ars2-depleted flies were not easily engi-
neered, though: transposon insertions or
constitutive RNAi were embryonic lethal.
This was unexpected, since ago2 or dcr2
knockouts are innocuous to Drosophila,
unlike miRNA pathway mutations. The
closest Ars2 homolog, the Arabidopsis
C2H2-Zinc-finger protein SERRATE (SE),
is required for pri-to-pre-miRNA process-
ing, and this hinted at the possibility that
Ars2 could be similarly required in the fly
miRNA pathway, in addition to its anti-
viral function. Ars2-depleted cells indeed
exhibited compromised miRNA functions,
owing to reduced pri-miRNA accumula-
tion. This suggested that Ars2 might stabi-
lize pri-miRNAs to facilitate their Micro-
processor-dependent nuclear conversion
into pre-miRNAs (Figure 1A). Coimmuno-
precipitation of Ars2 and Pasha in S2
cells further supported this idea. A report
from Gruber et al., in the same issue of
Cell, directly implicates human Ars2 in
pri-miRNA processing, and documents
its interaction with CBP80, a subunit of
the nuclear Cap-binding complex (CBC)e 6, August 20, 2009 ª2009 Elsevier Inc. 99
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Figure 1. Possible Scenarios Accounting for the Roles of Ars2 in miRNA Biogenesis and in
Antiviral Defense in Drosophila
(A) Most primary miRNA transcripts (pri-miRNA) are produced by RNA polII and thus have a polyA tail and
a 50 cap strucure (dark dot) which is protected from degradation by the nuclear Cap binding complex
(CBC) whose subunits CBP80 and CBP20 interact with Ars2 (dotted line). Cointeraction of Ars2 with the
CBC on one hand, and Drosha/Pasha on the other, would thus naturally bring the Microprocessor complex
into contact with the pri-miRNA and allow pre-miRNA processing. Alternatively, and as favored by the
authors, Ars2 could merely act as an enhancer or add precision to the action of the Microprocessor
that would bind to its pri-miRNA template independently of Ars2/CBC. Both models account for the faithful
excision of the pre-miRNA stem-loop structure, which, upon transport to the cytoplasm, is then processed
by Dcr1 into a single, mature miRNA species. One selected miRNA strand engages into Ago1 and allows
assembly of the miRNA-programmed RNA-induced silencing complex (miR-RISC) that scans the cell for
partially or fully complementary target mRNAs, shown here as undergoing translational repression.
(B) Most fly-infecting viruses such as those tested in Sabin et al. have a single-stranded RNA genome repli-
cated through the action of a viral-encoded replicase (Rep) thought to generate partially double-stranded
replication intermediates (RI). RIs may serve as direct templates for Dcr2, which, in association to Ars2,
might generate antiviral siRNAs that engage into Ago2. Note, however, that the contribution of Ars2 to
the production of viral-derived siRNAs was not documented in the study of Sabin et al. Viral silencing
suppressors, such as the B2 protein of FHV (red star), which is known to inhibit viral siRNA production,
might inhibit Ars2 function. The assembled siRNA-loaded RISC (siR-RISC) then suppresses viral RNA
accumulation through mechanisms that include endonucleolytic cleavage. Viral infections might stimulate
transcription of the Ars2 gene and also promote cytoplasmic relocalization of nuclear pools of Ars2.
(C) At least two nonmutually exclusive models could account for indirect antiviral effects of Ars2 in fly. Ars2
might be required for the documented, albeit mechanistically ill-defined, action of Dcr2 in promoting
production of the antiviral peptide Vago (left). Ars2 may also be required for production of miRNA-regu-
lating nonsilencing-based antiviral innate immune responses (e.g., JAK-STAT pathway) as has been found
in mammals (right). In the model, the miRNA repress a negative regulator (NR) of a host factor with intrinsic
antiviral (AV) activity. In both cases (right and left), depletion of Ars2 would result in enhanced virus
accumulation.(Gruber et al., 2009). Remarkably, Arabi-
dopsis with mutations in ABH1/CBP80
and CBP20 also show impaired pri-to-
pre-miRNA processing and exhibit devel-
opmental defects overlapping with those
of se mutants (Gregory et al., 2008; Lau-
binger et al., 2008). Sabin and colleagues100 Cell Host & Microbe 6, August 20, 2009confirmed that the fly Cbp20 immuno-
precipitates overexpressed Ars2, and that
Cbp20 or Cbp80 depletion compromises
silencing by miRNAs, and by exogenous
and endogenous siRNAs. Also as in
Ars2-depleted cells, pri-miRNA levels
were reduced in CBC-depleted S2 cells,ª2009 Elsevier Inc.which, furthermore, supported greater
replication of at least two viruses tested
in the siRNA pathway experiments de-
scribed above.
The work of Sabin et al. put forward
a tangible link between two fly silencing
pathways so far considered as largely
distinct: Ars2 could well represent a key
factor that permitted the evolutionary tran-
sition from a gene-regulatory pathway
operated by miRNAs to an innate immune
pathway operated by siRNAs, (or vice
versa, as it is presently impossible to state
confidently which arose first). Unlike Dcr1
and Ago1, Dcr2, and Ago2 are among
the fastest evolving 3% of all Drosophila
genes (Obbard et al., 2006), and it will
be interesting to investigate the extent to
which this signature of host pathogens
arms race is found in natural Ars2 variants
among arthropods. Besides, the study rai-
ses many questions. The most pressing
point is to clarify whether the roles of
Ars2 in antiviral defense and pri-to-pre-
miRNA processing entail similar mecha-
nisms. The first uncertainty pertains to
Ars2 expression and subcellular localiza-
tion. Hence, Gruber et al. show that human
Ars2 is nearly exclusively expressed in
dividing cells, where it facilitates the differ-
ential accumulation of miRNAs speci-
fying totipotency. Likewise, the role of
SERRATE was discovered through the
defects exhibited by se mutants in meri-
stems, the stem cell niches of plant
apexes. However, the fat body cells that
normally accumulate viruses in infected
adult flies are nonproliferating. Human
Ars2 and Arabidopsis SERRATE are also
very predominantly nuclear localized, yet
many viruses tested by Sabin et al. are
exclusively cytoplasmic. One testable
way to reconcile the data is to propose
that Ars2 is not only induced, but also cyto-
plasmically relocalized upon infection
(Figure 1B). Second, plant and animal pri-
miRNA are produced by PolII and, thus,
are 50-capped. This, evidently, provides
an ideal scenario as to how Ars2 might
recruit the Microprocessor to pri-miRNA
through its interaction with nuclear CBC
components (Figure 1A).A similar scenario
cannot, however, apply to the antiviral
Dcr2 complex, because at least one virus
tested by Sabin et al. replicates via uncap-
ped RNAs. The Sabin and Gruber studies
therefore propose that Ars2 is a general,
direct facilitator of cytoplasmic and
nuclear RNase III activities across species.
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sis extracts supports the above hypoth-
esis (Dong et al., 2008), it remains possible
that the mechanisms of Ars2-mediated
antiviral defense and Ars2-mediated
miRNA biogenesis overlap only partially.
First, quantitative and/or qualitative pro-
filing of viral small RNAs in wild-type (wt)
versus Ars2-depleted S2 cells should
provide stronger ground to the proposed
role of Ars2 as a direct modulator of
Dcr2-mediated processing of viral dsRNA
(Figure 1B). Such analyses might also
unravel specific viral RNA features resem-
bling those of pri-miRNAs, which could
preferentially attract Ars2 and Dicer-like
enzymes on both types of templates.
Limited changes in viral siRNA profiles
between the two cell types, on the other
hand, could point to more indirect contri-
butions of Ars2 to antiviral silencing. Note-
worthy, the induction of Vago, a cystein-
rich polypeptide with antiviral activity in
adult flies, requires the function of Dcr2
through as-yet-unspecified mechanisms
(Deddouche et al., 2008) (Figure 1C, left).
Possible alterations in the levels of Vago
(or other innate immune factors unrelated
to silencing) in Ars2-depeleted cells thus
warrant consideration. miRNAs also regu-
late innate and adaptive immunity across
kingdoms, and their frequent dismissal
as possible contributors to fly antiviral
defense is mostly attributable to the
unavailability of true dcr1 or ago1 hypo-
morphic mutations in Drosophila (Ding
and Voinnet, 2007). Based on these prem-ises, mysregulation of miRNA biogenesis
in Ars2-deficient cells might also con-
tribute indirectly to altered antiviral
immunity.
An important role for Ars2 in antiviral
silencing also predicts that it will be
targeted by one or several viral suppres-
sors of RNA silencing (VSR), which are
commonly deployed by insect and plant
viruses against critical steps of the
machinery (Ding and Voinnet, 2007). The
B2 protein of flock-house virus (FHV) is
a strong candidate because it binds FHV
replication complexes to directly inhibit
viral siRNA production by Dcr2 (Aliyari
et al., 2008) (Figure 1B, right). Targeting
of Ars2 by B2 might actually explain the
relatively modest effects of Ars2 depletion
observed by Sabin et al. on FHV replica-
tion. However, it is of note that expression
of B2, or indeed of any VSR studied so far
in Drosophila, incurs no apparent defects
in the miRNA pathway, yet RNAi is usually
strongly suppressed in S2 cells and adult
flies (Berry et al., 2009).
Ultimately, genetic studies might clarify
this question, particularly in flies, which
are highly amenable to forward and
reverse approaches. Use of available
sensor transgene reporting miRNA as well
as siRNA activities should facilitate the
identification of point mutation alleles
of Ars2 that could possibly uncouple its
involvements in the two pathways. Mean-
while, the study of Sabin and colleagues
prompts an evaluation of the antiviral
role of SERRATE in plants, which hasCell Host & Microbeeluded characterization so far. Based on
the findings of Gruber and colleagues,
use of meristem-infecting viruses or
geminiviruses known to induce plant cell
proliferation might constitute a reasonable
starting point in this endeavor.
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